Introduction
============

Plasma concentrations of cardiac-derived natriuretic peptides, specifically N-terminal pro-brain natriuretic peptide (NT-proBNP) and brain natriuretic peptide (BNP), have been firmly associated with cardiac function ([@b1-etm-0-0-8598],[@b2-etm-0-0-8598]). The increased release of those natriuretic peptides by cardiac myocytes into the bloodstream may be the result of increased ventricular wall stress, hypertrophy or volume overload. Therefore, measurement of the increased serum levels of these markers may have the potential to facilitate the accuracy of diagnosis and prognosis for patients with heart failure (HF), thereby improving the effectiveness of treatment strategies ([@b3-etm-0-0-8598]). Thus, these peptides are recognized as diagnostically and prognostically meaningful biomarkers for patients with HF ([@b4-etm-0-0-8598]).

Previous studies have also suggested that NT-proBNP may be an effective biomarker to diagnose left ventricular hypertrophy (LVH). To date, numerous studies have aimed to determine the associations of various natriuretic peptide levels with the risk of LVH in cardiovascular disease ([@b5-etm-0-0-8598],[@b6-etm-0-0-8598]). Most studies have focused on the association between natriuretic peptides and the diagnostic indices measured by echocardiography, particularly left ventricular diastolic dysfunction and left ventricular mass (LVM) index (LVMI) ([@b7-etm-0-0-8598]).

While the prognostic significance of the NT-proBNP regarding the risk of LVH has been evaluated in multiple research studies, the association of NT-proBNP quartiles with the risk of LVH in HF-negative patients remains to be explored. In addition, the association between the serum levels of NT-proBNP with measures of LVH, including LVMI, LVM and relative wall thickness (RWT), has been insufficiently investigated or reported. Therefore, the purpose of the present study was to determine how NT-proBNP levels, assessed in different quartiles, may affect the occurrence of LVH and to investigate the association between NT-proBNP and measures of LVH, including LVM, LVMI and RWT, in HF-negative patients.

Patients and methods
====================

### Patients

As the present study was a retrospective observational study, the requirement for patient consent and specifically ethical approval was waived. Medical records of 774 patients who received standard treatment at the Department of Cardiology of Tianjin Medical University General Hospital (Tianjin, China) between June 2015 and September 2015 were reviewed. The following exclusion criteria were then applied to the sample pool: i) Lack of critical clinical data; ii) serious primary conditions, including liver and renal failure, iii) other critical illnesses. The criteria for HF-negative status were established as the absence of any symptom that may contribute to the diagnosis of acute HF (AHF) or chronic HF (CHF). In terms of AHF, the diagnosis was confirmed on the basis of chest X-ray, which indicated cardiac congestion, as well as echocardiography revealing cardiac dysfunction and abnormally upregulated cardiac markers ([@b10-etm-0-0-8598]). In terms of CHF, in addition to the features of cardiac dysfunction, particularly echocardiography suggesting systolic or diastolic dysfunctions, the confirmative symptoms also included certain other somatic abnormalities, including swollen ankle, respiratory arrest and fatigue in a stationary body position or along with movements ([@b10-etm-0-0-8598]). Taking all of the above standards into account, 622 patients (age range, 16-89 years; mean age, 61.5±13 years; 366 males and 296 females) were finally included in the present study.

### Assays for biochemical indices and NT-proBNP

The biochemical indices and NT-proBNP were available from the patients\' medical records. The relevant detection methods are described below. Directly after fasting for 10 h, early in the morning, venipuncture of the antecubital vein was performed to collect a blood sample. All of the patient samples were delivered to the professional diagnostic laboratory for blood tests, including triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), uric acid (UA), alanine aminotransferase (ALT), fasting plasma glucose (FPG) and serum creatinine (Scr). Serum NT-proBNP levels were measured with an available immunoassay analyzer (Elecsys 2010; Roche Diagnostics). The quality control and quality assurance were in accordance with a standardized protocol and all the relevant parameters passed the professional assessments by the Clinical Laboratory of Tianjin Medical University General Hospital. The Clinical Laboratory of Tianjin Medical University General Hospital supplied the normal reference values.

### Echocardiography

A cardiology professional consistently performed all transthoracic echocardiography measurements. Using M-mode echocardiography, the cardiac indices were measured following standardized procedures from the American Society of Echocardiography, including ventricular internal dimension in end-diastole (LVIDd), interventricular septum thickness (IVST) in end-diastole and posterior wall thickness (PWT) in end-diastole ([@b11-etm-0-0-8598]). Based on the measurements of the above indices, the LVM was calculated depending on the Devereux formula: LVM (g)=1.04x\[(LVIDd+IVST+PWT)^3^-LVIDd^3^\]-13.6 g. The calculation of LVMI was in accordance with the following formula: LVMI (g/m^2^)=LVM/body surface area, while LVH was accordingly defined as LVMI ≥125 g/m^2^ in males and ≥120 g/m^2^ in females ([@b12-etm-0-0-8598]). The calculation of the relative wall thickness (RWT) was as follows: RWT=2xPWT/LVIDd ([@b11-etm-0-0-8598]). The RWT partition value was set at 0.45([@b13-etm-0-0-8598]). All subjects were stratified into four groups depending on LV characteristics: Normal LV geometry (normal LVMI and RWT), concentric LV remodeling (normal LVMI and increased RWT), eccentric LVH (increased LVMI and normal RWT) or concentric LVH (increased LVMI and RWT) ([@b14-etm-0-0-8598]).

### Statistical analysis

Statistical analyses were performed with SPSS 17.0 software (SPSS, Inc.). Continuous variables are presented as the mean ± standard deviation or as the median with interquartile range for those variables with a skewed distribution (assessed by Kolmogorov-Smirnov test), while categorical variables are presented as numbers and percentages. Differences between groups were analyzed using an independent-samples t-test, as well as a non-parametric test (Mann-Whitney U test) for sets of measurement data or the χ^2^ test for sets of categorical data. To normalize the concentration distribution, the logarithmic values of serum NT-proBNP levels were calculated. Accordingly, the association between Log(NT-proBNP) and LVM, LVMI and RWT were analyzed using multivariate linear regression. For influencing factors, including age, sex, hypertension, percutaneous coronary intervention (PCI), diabetes, smoking, heart rate (HR), body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), Scr, TC, TG, HDL-C, LDL-C, FPG, ALT and UA, corresponding adjustments were made. Using logistic regression analysis, the association between NT-proBNP quartiles and the risk of LVH was interpreted. Risk ratios (RRs) were presented with 95% CIs. All of the statistical comparisons were two-tailed and P\<0.05 was considered to indicate statistical significance.

Results
=======

### The occurrence of LVH increases progressively along with individual NT-proBNP quartiles in HF-negative patients without HF

To confirm the prognostic significance of NT-proBNP levels regarding the prevalence of LVH in patients without HF, they were stratified into groups of quartiles based on the NT-proBNP concentration in the present study: Quartile 1 (≤56.67 pg/ml), quartile 2 (56.95-119.50 pg/ml), quartile 3 (119.70-414.00 pg/ml) and quartile 4 (≥415.60 pg/ml). The basic clinical features of the testing groups are listed in [Table I](#tI-etm-0-0-8598){ref-type="table"}. Among the four groups, the following parameters were comparable without any significant variation: Sex, smoking history, previously diagnosed PCI, hypertension and diabetes. Age, HR, FPG, LVIDd, LVM and LVMI were statistically significant among the four groups. The number of patients with LVH in quartiles 1-4 were 44, 58, 64 and 108, respectively. The LVH prevalence rates in NT-proBNP quartiles 1-4 were 28.5, 34.9, 38.8 and 65.5%, respectively, as presented in [Fig. 1](#f1-etm-0-0-8598){ref-type="fig"}. The patients in quartile 4 had an increased LVH occurrence rate in comparison with that in the other quartiles and the LVH risk increased across the individual quartiles with a positive association with the NT-proBNP level.

### Association between NT-proBNP quartiles and LV geometric patterns

For an in-depth analysis of the correlation between NT-proBNP quartiles and LV geometric patterns, all participants were first stratified into four groups depending on their LVMI and RWT values, namely the normal LV geometry group, concentric remodeling group, eccentric LVH group and concentric LVH group. The prevalence rates of abnormal LV geometric patterns are presented for the concentric remodeling group, eccentric LVH group, eccentric LVH group and eccentric LVH group in [Fig. 2](#f2-etm-0-0-8598){ref-type="fig"} and were 16.9, 22.3, 24.2 and 45.5% in patients with NT-proBNP levels in quartiles 1, 2, 3 and 4, respectively. The prevalence rates of eccentric LVH between the lowest quartile and the highest quartile differed significantly. Compared with quartile 3, the prevalence rates of concentric remodeling and eccentric LVH were statistically different form quartile 4.

### Elevated NT-proBNP predicts LVH risk

The association of the NT-proBNP level with LVH risk was assessed using univariate and multivariate logistic regression ([Table II](#tII-etm-0-0-8598){ref-type="table"}). Univariate logistic regression indicated that the LVH risk values in quartiles 2, 3 and 4 were 1.489 (0.931-2.382), 1.757 (1.103-2.799) and 5.254 (3.281-8.413) fold of that in the quartile 1, respectively. The LVH prevalence rates also significantly varied among the three quartiles, as well as between the highest and lowest quartile (quartiles 4 and 1, respectively). After the results were adjusted for age, sex, hypertension, PCI, diabetes, smoking, HR, BMI, SBP, DBP, Scr, TC, TG, HDL-C, LDL-C, FPG, ALT and UA, multivariate logistic regression analysis was performed. Using the final multivariate model, the RRs for the LVH risk of patients in quartiles 2, 3 and 4 compared with those in quartile 1 were 1.683 (1.015-2.792), 1.800 (1.071-3.025) and 5.679 (3.225-9.999), respectively. Overall, patients in quartiles 2, 3 and 4 had a significantly higher LVH prevalence rate compared with patients in quartile 1; in summary the results indicated that patients with elevated NT-proBNP were significantly more likely to develop LVH.

### Serum NT-proBNP is positively correlated with LVM and LVMI, while it is inversely correlated with RWT

To substantiate the association between NT-proBNP and LVM, LVMI and RWT, two types of regression analyses were performed. The linear regression results indicated a positive association between Log(NT-proBNP) and LVM (P\<0.001; [Fig. 3](#f3-etm-0-0-8598){ref-type="fig"}) and LVMI (P\<0.001; [Fig. 4](#f4-etm-0-0-8598){ref-type="fig"}), while an inverse correlation between Log(NT-proBNP) and RWT was indicated (P\<0.05; [Fig. 5](#f5-etm-0-0-8598){ref-type="fig"}). Using the multivariate regression model, significant associations between Log(NT-proBNP) and LVM, LVMI and RWT were confirmed after adjustment for age, sex, hypertension, PCI, diabetes, smoking history, HR, BMI, SBP, DBP, Scr, TC, TG, HDL-C, LDL-C, FPG, ALT and UA, as presented in [Table III](#tIII-etm-0-0-8598){ref-type="table"}.

Discussion
==========

Accumulating studies suggest that inherent and acquired abnormalities within the natriuretic peptide system may contribute to the occurrence of a series of systemic and cardiac diseases, particularly cardiac hypertrophy ([@b2-etm-0-0-8598]). NT-proBNP is a BNP precursor released by ventricular tissues in response to an aggravated ventricular burden, which may induce ventricle remodeling. The preliminary NT-proBNP has a relatively large molecular size, as well as a longer half-life than the active form; therefore, its measurement is comparably convenient and is less likely to be interfered with by acute changes that may markedly affect the levels of other natriuretic peptides ([@b15-etm-0-0-8598]). As the relative stability of NT-proBNP enhances its reliability as a ventricular stress indicator and as a potential prognostic indicator, the serum levels of NT-proBNP were selected as the candidate biomarker to be investigated in the present study.

Previous studies have proved that NT-proBNP is an effective marker for LVH diagnosis. For instance, a population study indicated that NT-proBNP levels were elevated in LVH regardless of hypertension diagnosis ([@b6-etm-0-0-8598]). NT-proBNP measurements were also proved to be significant to LVH diagnosis for patients in the 1st year after renal transplantation ([@b16-etm-0-0-8598]) and were correlated with left ventricular dysfunction in dialysis patients ([@b17-etm-0-0-8598]). The present study provided an in-depth insight into the risk of LVH predicted by NT-proBNP quartiles and the complex association of NT-proBNP with LVM, LVMI and RWT in HF-negative patients. The results indicated that the prevalence rate of LVH increased progressively across individual NT-proBNP quartiles in patients without HF. The prevalence rate of abnormal LV geometric patterns was highest in the concentric remodeling group in NT-proBNP quartile 1 and in the eccentric LVH group in quartiles 2-4. According to univariate logistic regression, patients in NT-proBNP quartile 4 and quartile 3 had a 5.254- and a 1.757-fold increased LVH risk compared to patients in NT-proBNP quartile 1, respectively. Multivariate logistic regression also indicated that, compared with that of patients in NT-proBNP quartile 1, patients in NT-proBNP quartiles 2-4 had a significantly increased LVH risk. Furthermore, significant positive linear correlations of NT-proBNP with LVM and LVMI were identified, while an inverse correlation of NT-proBNP with RWT was indicated. After adjustments with the consideration of multiple potential interferences, including clinical parameters and predisposing conditions, significant associations between NT-proBNP and LVM, LVMI and RWT were further confirmed.

Numerous clinical studies have reported an association between upregulated natriuretic peptides and abnormally increased blood pressure. For instance, according to a cross-sectional study involving 202 participants with a previous history of dyspnea, the median NT-proBNP level was increased by 60% in hypertension-positive participants in comparison with hypertension-negative participants ([@b18-etm-0-0-8598]). A prospective analysis involving 1,801 participants reported that upregulated BNP plasma levels were significantly correlated with an elevated risk of aggravated hypertension occurring four years later for males rather than females ([@b19-etm-0-0-8598]). Bower *et al* ([@b20-etm-0-0-8598]) reported that participants in the lowest NT-proBNP quartile had a minimum risk of hypertension in comparison with any of the upper quartiles. In detail, the hypertension risks in the order from the lowest to the highest NT-proBNP quartiles were 1.00 at baseline (reference), 1.10 (95% CI: 0.97-1.24), 1.08 (95% CI: 0.95-1.24), and 1.24 (1.08-1.42), respectively. It also indicated that the log-unit increase of NT-proBNP corresponded to an 8% increase of the hypertension risk (95% CI: 1.03-1.13) ([@b20-etm-0-0-8598]). In addition, hypertension was generally considered to be the predominant predisposing factor for LVH, which was suggested to be the result of excessive left ventricular afterload. Thus, it may be speculated that individuals with upregulated NT-proBNP were at increased risk of LVH, which may be associated with hypertension.

Accumulating studies suggested that inflammatory reactions may have a critical influence on the pathophysiological mechanisms of LVH ([@b21-etm-0-0-8598],[@b22-etm-0-0-8598]). Animal studies also indicated a critical role of inflammatory cytokines in the pathogenesis of LVH. Zhao *et al* ([@b23-etm-0-0-8598]) reported that genetic deletion of interleukin (IL)-6 attenuates transverse aortic constriction-induced LVH and LV dysfunction in mice. According to previous research, in a population of asymptomatic patients with high blood pressure, upregulated BNP was correlated with increased levels of inflammatory cytokines, including tumor necrosis factor-α, IL-6 and IL-8 and also associated with increased LVMI and left atrial volume index ([@b24-etm-0-0-8598]). Furthermore, according to certain animal studies, BNPs have important roles in the regulation of myocardial fibrosis ([@b25-etm-0-0-8598],[@b26-etm-0-0-8598]). Excessive interstitial fibrosis was observed even in patients at the early stage of hypertension with only moderately upregulated LVH ([@b27-etm-0-0-8598],[@b28-etm-0-0-8598]). In addition, certain studies have reported that regression of the fibrosis degree resulted in improved LV function ([@b29-etm-0-0-8598],[@b30-etm-0-0-8598]). Thus, it may be speculated that the natriuretic peptide levels are clinically significant markers for the preliminary subclinical pathological process involving inflammation, myocardial fibrosis and cardiac remodeling.

In conclusion, the present study examined the association between NT-proBNP and LVH risk and the association between NT-proBNP and LVH hallmarks in patients without HF. Therefore, whether NT-proBNP levels have potential diagnostic, prognostic and epidemiological implications regarding LVH in patients without HF still requires in-depth investigation by further studies. However, the present study had several limitations. First, the study was observational. Furthermore, only patients who were admitted to the cardiology department were enrolled and due to lack of their NT-proBNP data, no healthy subjects were included for reference. More importantly, the sample size was limited and the results of the present study require further verification by studies with an extended scope.
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###### 

Clinical characteristics of the study subjects in N-terminal pro-brain natriuretic peptide quartiles.

  Item                                                                     Total (n=622)   Quartile 1 ≤56.67 pg/ml (n=166)   Quartile 2 56.95-119.50 pg/ml (n=166)   Quartile 3 119.70-414.00 pg/ml (n=165)   Quartile 4 ≥415.60 pg/ml (n=165)   P-value
  ------------------------------------------------------------------------ --------------- --------------------------------- --------------------------------------- ---------------------------------------- ---------------------------------- ---------
  Male sex (%)                                                             366 (55.3)      102 (61.4)                        81 (48.8)                               90 (54.5)                                93 (56.4)                          0.139
  Age (years)                                                              61.48±12.85     54.48±12.64                       59.60±11.75                             63.81±11.75                              67.97±11.15                        \<0.001
  Hypertension (%)                                                         446 (71.7)      113 (68.1)                        108 (65.1)                              107 (64.8)                               118 (71.5)                         0.531
  PCI (%)                                                                  193 (31.0)      30 (18.1)                         36 (21.7)                               56 (33.9)                                71 (43.0)                          0.613
  Diabetes (%)                                                             171 (27.5)      38 (22.9)                         41 (24.7)                               45 (27.3)                                47 (28.5)                          0.613
  Smokers (%)                                                              287 (46.1)      76 (45.8)                         67 (40.4)                               69 (41.8)                                75 (45.5)                          0.692
  HR (bpm) (%)                                                             72.28±15.19     72.20±11.01                       69.84±12.96                             69.07±14.57                              77.98±19.46                        \<0.001
  BMI (kg/m^2^)                                                            25.71±3.56      26.56±3,60                        25.34±3.53                              25.46±3.53                               25.53±3.48                         0.006
  SBP (mmHg)                                                               137.76±47.11    136.50±18.99                      137.88±18.69                            137.35±20.31                             137.36±23.79                       0.924
  DBP (mmHg)                                                               80.44±13.58     83.52±12.94                       80.21±13.46                             80.36±12.46                              77.72±14.85                        0.002
  Scr (umol/l) (62-133)^[a](#tfn1-etm-0-0-8598){ref-type="table-fn"}^      72.60±35.95     66.23±14.53                       71.17±15.07                             72.52±20.42                              80.71±37.10                        0.003
  TC (mmol/l) (3.59-5.17)^[a](#tfn1-etm-0-0-8598){ref-type="table-fn"}^    4.36±1.05       4.40±0.94                         4.4.26±0.95                             4.36±0.1.08                              4.44±1.22                          0.495
  TG (mmol/l) (0.57-1.71)^[a](#tfn1-etm-0-0-8598){ref-type="table-fn"}^    1.60±1.24       1.75±1.26                         1.48±1.10                               1.56±1.04                                1.62±1.51                          0.272
  HDL (mmol/l) (0.80-2.20)^[a](#tfn1-etm-0-0-8598){ref-type="table-fn"}^   1.07±0.33       1.04±0.26                         1.13±0.43                               1.08±0.33                                1.05±0.28                          0.050
  LDL (mmol/l) (1.33-3.36)^[a](#tfn1-etm-0-0-8598){ref-type="table-fn"}^   2.61±0.89       2.62±0.82                         2.49±0.82                               2.60±0.89                                2.73±1.02                          0.109
  FPG (mmol/l) (3.6-5.8)^[a](#tfn1-etm-0-0-8598){ref-type="table-fn"}^     5.82±2.03       5.44±1.62                         5.56±1.62                               5.76±1.84                                6.50±2.68                          \<0.001
  ALT (U/l) (5-40)^[a](#tfn1-etm-0-0-8598){ref-type="table-fn"}^           25.95±38.72     25.96±18.7                        23.81±20.38                             23.99±20.80                              26.85±21.83                        0.538
  UA (µmol/l) (140-414)^[a](#tfn1-etm-0-0-8598){ref-type="table-fn"}^      356.13±108.82   362.45±105.91                     341.44±91.99                            350.25±97.81                             371.82±122.13                      0.046
  LVIDd (mm)                                                               48.59±4.57      47.53±3.66                        47.93±4.15                              48.33±4.42                               50.54±5.31                         \<0.001
  IVST (mm)                                                                10.37±1.59      10.29±1.33                        10.11±1.26                              10.38±1.53                               10.70±2.07                         0.008
  PWT (mm)                                                                 10.26±1.29      10.20±1.25                        10.06±1.19                              10.24±1.20                               10.52±1.44                         0.011
  LVM (g)                                                                  215.60±59.91    205.57±52.31                      203.84±52.13                            212.67±55.18                             240.54±71.26                       \<0.001
  LVMI (g/m^2^)                                                            121.11±31.02    111.28±23.87                      114.66±25.52                            121.71±29.78                             136.87±37.10                       \<0.001
  RWT                                                                      0.42±0.06       0.43±0.05                         0.42±0.06                               0.42±0.05                                0.42±0.06                          0.376

Values are expressed as the mean ± standard deviation or n (%).

^a^Normal ranges of laboratory parameters as indicated by the Clinical Laboratory of Tianjin Medical University General Hospital. PCI, percutaneous coronary intervention; HR, heart rate; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; Scr, serum creatinine; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FPG, fasting plasma glucose; ALT, alanine aminotransferase; UA, uric acid; LVIDd, LV internal dimension in end-diastole; IVST, interventricular septum thickness; PWT, posterior wall thickness; LVM, left ventricular mass; LVMI, LVM index; RWT, relative wall thickness.

###### 

Uni- and multivariate logistic regression models describing the risk for the prevalence rate of LVH in the study subjects.

                            Model 1               Model 2                         
  ------------------------- --------------------- --------- --------------------- ---------
  NT-pro BNP quartile                                                             
  1 (≤56.67 pg/ml)          1                     \-        1                     \-
  2 (56.95-119.50 pg/ml)    1.489 (0.931-2.382)   0.097     1.683 (1.015-2.792)   0.044
  3 (119.70-414.00 pg/ml)   1.757 (1.103-2.799)   0.018     1.800 (1.071-3.025)   0.027
  4 (≥415.60 pg/ml)         5.254 (3.281-8.413)   \<0.001   5.679 (3.225-9.999)   \<0.001
  Age (years)                                               1.014 (0.997-1.031)   0.115
  Male sex                                                  1.104 (0.694-1.756)   0.677
  Hypertension                                              1.524 (1.016-2.287)   0.042
  PCI                                                       1.183 (0.791-1.769)   0.414
  Diabetes                                                  1.488 (0.922-2.401)   0.103
  Smoking                                                   1.637 (1.085-2.470)   0.019
  HR (bpm)                                                  0.991 (0.980-1.003)   0.142
  BMI (kg/m^2^)                                             0.991 (0.939-1.045)   0.731
  SBP (mmHg)                                                1.000 (0.996-1.004)   0.975
  DBP (mmHg)                                                1.025 (1.009-1.041)   0.002
  Scr (mmol/l)                                              0.997 (0.989-1.004)   0.372
  TC (mmol/l)                                               0.451 (0.187-1.090)   0.077
  TG (mmol/l)                                               1.242 (0.942-1.638)   0.125
  HDL-C (mmol/l)                                            1.486 (0.555-3.976)   0.430
  LDL-C (mmol/l)                                            2.327 (0.946-5.724)   0.066
  FPG (mmol/l)                                              1.033 (0.924-1.154)   0.569
  ALT (U/l)                                                 1.000 (0.995-1.004)   0.928
  UA (µmol/l)                                               1.001 (0.999-1.003)   0.600

Model 1: Univariate logistic regression model describing the risk for the incidence of LVH in the study subjects. Model 2: Multivariate logistic regression model adjusting for age, gender, hypertension, PCI, diabetes, smoking, HR, BMI, SBP, DBP; Scr, TC, TG, HDL-C, LDL-C, FPG, ALT and UA. HR, heart rate; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; Scr, serum creatinine; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FPG, fasting plasma glucose; ALT, alanine aminotransferase; UA, uric acid; RR, risk ratio; PCI, percutaneous coronary intervention; NT-proBNP, N-terminal pro-brain natriuretic peptide.

###### 

Results of multivariate modelling for Lg(NT-proBNP) (n=662).

                   RWT       LVM      LVMI                                                     
  ---------------- --------- -------- --------- --------- -------- --------- -------- -------- ---------
  Lg(NT-proBNP)    -0.009    -2.138   0.033     26.388    7.604    \<0.001   16.674   8.065    \<0.001
  Male sex         0.004     0.667    0.505     -32.883   -6.789   \<0.001   -4.167   -1.444   0.149
  Age (years)      \<0.001   1.416    0.157     -0.143    -0.832   0.406     0.029    0.289    0.773
  Hypertension     0.024     4.512    \<0.001   13.170    3.128    0.002     6.587    2.626    0.009
  PCI              -0.012    -2.177   0.030     -1.150    -0.269   0.788     0.226    0.089    0.929
  Diabetes         -0.003    -0.478   0.633     4.511     0.885    0.376     5.271    1.736    0.083
  Smoking          \<0.001   0.021    0.983     13.252    3.051    0.002     6.514    2.517    0.012
  HR (bpm)         \<0.001   1.055    0.292     0.039     0.318    0.750     -0.010   -0.131   0.896
  BMI (kg/m^2^)    \<0.001   0.530    0.596     4.617     8.252    \<0.001   0.110    0.330    0.742
  SBP (mmHg)       \<0.001   1.344    0.179     0.016     0.403    0.687     0.011    0.469    0.639
  DBP (mmHg)       0.001     2.943    0.003     0.501     3.142    0.002     0.341    3.587    \<0.001
  Scr (mmol/l)     \<0.001   2.597    0.010     -0.034    -0.632   0.528     -0.017   -0.533   0.594
  TC (mmol/l)      0.008     0.783    0.434     -5.955    -0.714   0.475     -2.729   -0.549   0.583
  TG (mmol/l)      -0.003    -1.081   0.280     1.284     0.529    0.597     0.400    0.277    0.782
  HDL-C (mmol/l)   -0.014    -1.191   0.234     1.355     0.141    0.888     -1.782   -0.311   0.756
  LDL-C (mmol/l)   -0.011    -1.017   0.310     6.909     0.815    0.415     2.985    0.591    0.555
  FPG (mmol/l)     0.002     1.185    0.237     0.947     0.815    0.416     0.223    0.322    0.748
  ALT (U/l)        \<0.001   -0.391   0.696     -0.039    -0.820   0.413     -0.008   -0.267   0.789
  UA (µmol/l)      \<0.001   -0.022   0.982     0.022     1.119    0.026     0.014    1.187    0.236

PCI, percutaneous coronary intervention; HR, heart rate; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; Scr, serum creatinine; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FPG, fasting plasma glucose; ALT, alanine aminotransferase; UA, uric acid; RWT, relative wall thickness; LVM, left ventricular mass; LVMI, LVM index; β, standard β-coefficient; NT-proBNP, N-terminal pro-brain natriuretic peptide.
